Search Results

56 results

  1. CORESTA Congress, Kunming, 2018, Smoke Science/Product Technology Groups, ST 25

    Misperception of e-cigarette harm growing among American adults, 2013-2015

    VERRON T.(1); GUO M.(1); VARIGNON B.(1); O'CONNELL G.(2); WALELE T.(2); CAHOURS X.(1)
    (1) SEITA - Imperial Brands plc, Paris, France; (2) Fontem Ventures B.V., Amsterdam, The Netherlands
    Electronic cigarettes (e cigarettes) have been characterised as significantly less harmful than smoked tobacco by an increasing number of public health authorities. However, the proportion of American adults who perceive e cigarettes to be equally or more ...
  2. CORESTA Congress, Kunming, 2018, Smoke Science/Product Technology Groups, STPOST 52

    Biological test procedure for fresh generated cigarette smoke and e-cigarette aerosols under air-liquid interface (ALI) exposure in 24 and 96 multi-well plates

    WIECZOREK R.(1); TRELLES STICKEN E.(1); WALELE T.(2); CZEKALA L.(3); SIMMS L.(3)
    (1) Reemtsma Cigarettenfabriken GmbH, Imperial Brands plc, Hamburg, Germany; (2) Fontem Ventures, Amsterdam, The Netherlands; (3) Imperial Tobacco Limited, Bristol, U.K.
    Cigarette smoke and e cigarette aerosol contain particulate matter/liquid droplets in the solid phase as well as volatile substances in the gas phase. Both fractions are of potential toxicological relevance and should be considered when assessing ...
  3. CORESTA Congress, Kunming, 2018, Smoke Science/Product Technology Groups, STPOST 53

    Use of human derived cell lines to increase the biological relevance of cigarette condensate, non-tobacco materials and e-liquids testing

    WIECZOREK R.(1); TRELLES STICKEN E.(1); WALELE T.(2); CZEKALA L.(3); SIMMS L.(3)
    (1) Reemtsma Cigarettenfabriken GmbH, Imperial Brands plc, Hamburg, Germany; (2) Fontem Ventures, Amsterdam, The Netherlands; (3) Imperial Tobacco Limited, Bristol, U.K.
    The in vitro testing strategy of tobacco products is mainly based on the testing of extracts from cigarette smoke condensates. An accepted industry wide assay battery has been developed over recent years which delivers reliable results for the ...
  4. TSRC, Tob. Sci. Res. Conf., 2018, 72, abstr. 005

    Effect of the addition of SBA-15 in the pyrolysis of a reference tobacco under inert and oxidizing atmosphere

    CALABUIG E.; MARCILLA A.; BELTRÁN M.I.
    University of Alicante, San Vicente del Raspeig, Spain
    The composition of evolved products from slow pyrolysis under inert and oxidizing atmospheres of a reference tobacco 3R4F from the Reference Cigarette Program of the College of Agriculture of the University of Kentucky and a mixture of the reference ...
  5. TSRC, Tob. Sci. Res. Conf., 2018, 72, abstr. 034

    Influence of the time of synthesis of SBA-15 on its effect as a catalyst reducing toxicant concentration in tobacco smoke

    JUÁREZ-SERRANO N.; MARCILLA A.; BELTRÁN M.I.
    University of Alicante, San Vicente del Raspeig, Spain
    In recent years, SBA-15 has been suggested as an additive for reduction of toxic compounds in tobacco smoke. The structure of this type of materials is strongly dependent on the synthesis conditions. The objective of the present work is to analyze the ...
  6. CORESTA Meeting, Smoke Science/Product Technology, 2017, Kitzbühel, ST 62

    Overview of in vitro methods used to assess e-cigarettes based on “Toxicity Testing in 21st Century” principles

    SIMMS L.(1); STEVENSON M.(1); CZEKALA L.(1); TSCHIERSKE N.(1); WALELE T.(2)
    (1) Imperial Tobacco Ltd, Bristol, U.K.; (2) Fontem Ventures B.V. (an Imperial Brands PLC Company), Amsterdam, The Netherlands
    When the National Academies of Sciences released “Toxicity Testing in the 21st Century: A Vision and a Strategy” a new toxicological paradigm was created, focusing on the use of human cell lines and the disruption of key cellular pathways. In keeping with ...
  7. CORESTA Meeting, Smoke Science/Product Technology, 2017, Kitzbühel, STPOST 08

    Indoor air quality and surface deposition assessment following use of an open system e-cigarette

    BAUER N.(1); TSCHIERSKE N.(1); O'CONNELL G.(2); CAHOURS X.(3)
    (1) Reemtsma Cigarettenfabriken GmbH (an Imperial Brands PLC Company), Hamburg, Germany; (2) Fontem Ventures B.V. (an Imperial Brands PLC Company), Amsterdam, The Netherlands; (3) SEITA-Imperial Tobacco Limited, Fleury-les-Aubrais, France
    Electronic cigarette (e-cigarette) nicotine delivery devices are growing in popularity worldwide. Both regulators and public health organisations are beginning to examine potential implications that exposure to exhaled e-cigarette aerosol may have on non ...
  8. CORESTA Meeting, Smoke Science/Product Technology, 2017, Kitzbühel, STPOST 21

    The use of in vitro human biomarkers from relevant primary cell lines, to assess the effects of increasing nicotine concentration in e-liquids

    SIMMS L.(1); STEVENSON M.(1); CZEKALA L.(1); TSCHIERSKE N.(1); BERG E.(2); WALELE T.(3)
    (1) Imperial Tobacco Ltd, Bristol, U.K.; (2) DiscoverX Corporation, Fremont, CA, U.S.A.; (3) Fontem Ventures B.V. (an Imperial Brands PLC Company), Amsterdam, The Netherlands
    As part of the ongoing stewardship of electronic cigarettes, and in line with the National Academies of Sciences “ Toxicity Testing in the 21st Century: A Vision and a Strategy ”, Fontem Ventures B.V. have investigated the utility of a series of endpoints ...
  9. CORESTA Congress, Berlin, 2016, Smoke Science/Product Technology Groups, ST 04

    Reduction of harmful or potentially harmful constituents (HPHCs) following partial or complete substitution of cigarettes with electronic cigarettes in adult smokers

    D’RUIZ C.D.(1); O’CONNELL G.(2); GRAFF D.W.(3)
    (1) Scientific Affairs Consultant, Fontem Ventures, B.V., Greensboro, NC, U.S.A.; (2) Fontem Ventures, B.V., Scientific and Regulatory Affairs, Amsterdam, The Netherlands; (3) Celerion, Lincoln, NE, U.S.A.
    Changes in fifteen urine, blood, and exhaled breath biomarkers of exposure (BoE) to harmful and potentially harmful constituents (HPHCs), representing major classes of compounds reported by the FDA to be significant contributors to smoking-associated ...